Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2

N Firouzabadi, P Ghasemiyeh, F Moradishooli… - International …, 2023 - Elsevier
It has been more than three years since the first emergence of coronavirus disease 2019
(COVID-19) and millions of lives have been taken to date. Like most pandemics caused by …

A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines

P Ghasemiyeh, S Mohammadi-Samani… - International …, 2021 - Elsevier
20 months has been passed since the detection of the first cases of SARS-CoV-2 infection
named COVID-19 from Wuhan city of China. This novel coronavirus spread rapidly around …

Favipiravir use in COVID-19: analysis of suspected adverse drug events reported in the WHO database

RJ Kaur, J Charan, S Dutta, P Sharma… - Infection and drug …, 2020 - Taylor & Francis
Background COVID-19 caused by SARS-CoV-2 virus emerged as an unprecedented
challenge to discover effective drugs for its prevention and cure. Hyperinflammation-induced …

Neurological consequences of SARS-CoV-2 infection and concurrence of treatment-induced neuropsychiatric adverse events in COVID-19 patients: navigating the …

P Borah, PK Deb, B Chandrasekaran… - Frontiers in molecular …, 2021 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to the angiotensin-
converting enzyme 2 (ACE2) receptor and invade the human cells to cause COVID-19 …

[HTML][HTML] Peripheral neuropathy in COVID-19 is due to immune-mechanisms, pre-existing risk factors, anti-viral drugs, or bedding in the Intensive Care Unit

J Finsterer, FA Scorza, CA Scorza… - Arquivos de neuro …, 2021 - SciELO Brasil
Background: This mini-review aims to summarize and discuss previous and recent
advances in the clinical presentation, pathophysiology, diagnosis, treatment, and outcome of …

Intensive care unit‐acquired weakness and the COVID‐19 pandemic: a clinical review

ES Qin, CL Hough, J Andrews, AE Bunnell - PM&R, 2022 - Wiley Online Library
Patients with severe cases of coronavirus disease 2019 (COVID‐19) often become critically
ill requiring intensive care unit (ICU) management. These individuals are at risk for …

Clinical features and cognitive sequelae in COVID-19: a retrospective study on N=152 patients

MR Manera, E Fiabane, D Pain, EN Aiello, A Radici… - Neurological …, 2022 - Springer
Background The novel human coronavirus (SARS-CoV-2) shows neurotropism and
systemically affects the central nervous system (CNS). Cognitive deficits have been indeed …

Clinical and pathophysiologic spectrum of neuro-COVID

J Finsterer, FA Scorza - Molecular Neurobiology, 2021 - Springer
Though the lungs are predominantly affected in SARS-CoV-2-infected patients, extra-
pulmonary manifestations can occur. Extra-pulmonary manifestations of the central and …

Insights into neurological dysfunction of critically ill COVID-19 patients

C Deana, L Verriello, G Pauletto, F Corradi… - Trends in Anaesthesia …, 2021 - Elsevier
Novel coronavirus spread rapidly around the world infecting millions of people. It was thus
declared a pandemic. This new virus damages the lungs. In the most severe cases, it leads …

COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development

N Bostanghadiri, P Ziaeefar, MG Mofrad… - BioMed Research …, 2023 - Wiley Online Library
The world is presently in crisis facing an outbreak of a health‐threatening microorganism
known as COVID‐19, responsible for causing uncommon viral pneumonia in humans. The …